ImmunityBio, Inc. (IBRX) witnessed a significant pre-market surge of 5.23% on Friday, driven by investor enthusiasm over the company's plans to submit multiple treatments for approval by the U.S. Food and Drug Administration (FDA) in 2025.
The biopharmaceutical company announced that it would file a supplemental biologics license application (BLA) for the treatment of bladder cancer. If approved by the FDA, this BLA would allow ImmunityBio to commercialize its product across the United States.
Additionally, the company aims to submit another BLA for the treatment of a specific type of lung cancer. Investors were further encouraged by the positive results from a Phase 2B study, which demonstrated the efficacy of ImmunityBio's Anktiva drug in combination with other inhibitors for patients who had failed first and second-line treatment attempts.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。